// App-Quantinova.ai

11 : Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC).

Researchers

Presenter

  • Kate Lynette Mahon

Principal Investigators

  • Wenjia Qu

  • James Devaney

  • Girish Mallesara Hiriyanna Gowda

  • Peter Molloy

  • Lisa Horvath

  • Susan J. Clark

  • Cheryl Paul

  • Lesley Castillo

  • Richard Wykes

  • Mark D Chatfield

  • Michael J. Boyer

  • Martin R. Stockler

  • Gavin M. Marx

  • Howard Gurney

Medical Centers

  • CSIRO, Sydney, Australia

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Northern Haematology and Oncology Group, Sydney, Australia

  • Menzies School of Health Research, Darwin, Australia

  • Chris OBrien Lifehouse/Royal Prince Alfred Hospital, Sydney, Australia

  • Newcastle Mater Misericordiae Hospital, Newcastle, Australia

  • The Kinghorn Cancer Centre, The Garvan Institute of Medical Research, Sydney, Australia

  • National Centre for Biomedical Engineering Science, Galway, Ireland

  • The Garvan Institute of Medical Research, Sydney, Australia

  • Westmead Hospital and University of Sydney, Sydney, Australia

Locations

  • Ireland

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • glutathione

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved